en · de · es · fr · pt
bpc-157-notes.peptides6155.com › Info › Background And Chemical Identity — Research Overview

Background And Chemical Identity — Research Overview

By Editorial Desk · published 2025-12-14 · last reviewed 2026-01-17 · Info

pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.

Background and Chemical Identity

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Handling, Stability, and Quality Checks

The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.

Bpc-157 at a glance

PropertyValueNotes
Molar massApproximately 1419.5 g/molCalculated from the reported 15-residue sequence
Molecular formulaC62H98N16O22Based on the same sequence
AppearanceWhite to off-white powderTypical of a lyophilized preparation
Solubility classFreely soluble in waterAlso dissolves in saline solutions
Typical storage temperatureMinus 20 degrees Celsius, dryRefrigeration advised after reconstitution

Handling, Stability, and Analysis

Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.

Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.

Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.

Related pages on this site

Identity And Chemical Background

The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.

Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.

Notes from published material

==== Eliminated in primary ==== Earnest Clayton, public health professional Peter Filler, teacher and nominee for the 2nd district in 2024 Todd Ivey, physician Marty Rocha, deputy sheriff and nominee for Texas's 28th House of Representatives district in 2024 Terry Virts, retired United States Air Force pilot and NASA astronaut (previously ran for U.S. Senate)

==== Cells ==== Cells that line surfaces exposed to the outside world or gastrointestinal tract (epithelia) or internal cavities (endothelium) come in numerous shapes and forms – from single layers of flat cells, to cells with small beating hair-like cilia in the lungs, to column-like cells that line the stomach. Endothelial cells are cells that line internal cavities including blood vessels and glands. Lining cells regulate what can and cannot pass through them, protect internal structures, and function as sensory surfaces.

=== Phase 3 === Botulinum toxin A (AboBoNT-A; AbobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A; Dysport; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [1] Botulinum toxin A (Bocouture; Incobotulinum toxin A; NT-201; Vibe/Xeomin; ViXe; Xeomeen; Xeomin; Zeomaine) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [2] Eptinezumab (ALD-403; Lu-AG09221; Vyepti) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache [3] Naproxen/rizatriptan (rizatriptan/naproxen) – combination of naproxen (COX inhibitor/NSAID) and rizatriptan (triptan) – migraine [4] Promethazine/sumatriptan (CL-H1T) – combination of promethazine (anthistamine, anticholinergic, other actions) and sumatriptan (triptan) – migraine [5]

== Reconstitution of the tablets == The cuneiform tablets confirming Amat-Mamu's inheritance were stored in the home of her uncle, Ikun-pī-Sîn. They were kept separate from the family archive so as not to suggest that the inheritance was part of the family estate. It is unknown why they were kept in her uncle's house, though such storage arrangements with family members were not uncommon. When they were lost, her father Sîn-ilî had a deposition taken from the uncle admitting to their loss. Amat-Mamu was forced to go to the court so the judges could authorize the creation of new tablets. The tablets that Belessunu received as a girl during her own adoption were not reconstituted, for her and her witnesses to that contract had already died. The court also ruled that should the previous tablets be found, they were still the sole property of Amat-Mamu. The sequence of events describing both the legal dispute and the tablets' loss was documented on the reconstituted tablet. The reconstitution meant that some details were lost and inconsistencies were introduced, primarily in the description of the fields. The tablet is dated to the 14th year of Samsu-iluna's rule, placing its creation around 1736 BC. It has been preserved and is designated by archeologists as CT 47.63. Amat-Mamu's story is listed on the tablet alongside that of Belessunu, including Belessunu's dedication as a nadītu and her adoption by her aunt. The tablet is used in the modern era as a reference to understand Babylonian property and inheritance law.

Sources: en.wikipedia.org

Further detail

== Skin contracture == Wound contraction, where the edges of the skin are pulled together to close the wound, is a normal part of wound healing. However, large wounds and abnormal wound healing cause skin contractures by excessively tightening the skin and limiting movement. A skin contracture due to a burn is known as a burn scar contracture. Large areas of missing skin (such as large burns, grazes, and gouges) drastically reduce the area of skin causing it to become tight when pulled together during wound healing. Scars initially lack elasticity with synthesis of elastic tissue fibres (elastogenesis) being a function of duration and site of the scar. Deep wounds and abnormal wound healing causes abnormal scarring such as hypertrophic scars. Studies on hypertrophic scars have shown a lack of improvement to both elasticity and stiffness suggesting a prolonged healing phase without amelioration seen in a normal wound-healing curve. Surgery can help alleviate skin contractures in the form of skin grafts and removal of hypertrophic scars. For hypertrophic scars, timing is important when considering surgery, as over time scars will mature and may show decreased contractures along with flattening, softening, and repigmentation without surgical intervention.

Polysubstance use or poly drug use refers to the use of combined psychoactive substances. Polysubstance use may be used for entheogenic, recreational, or off-label indications, with both legal and illegal substances. In many cases one drug is used as a base or primary drug, with additional drugs to leaven or compensate for the side effects, or tolerance, of the primary drug and make the experience more enjoyable with drug synergy effects, or to supplement for primary drug when supply is low.

In contemporary Western use, turquoise is most often encountered cut en cabochon in silver rings, bracelets, often in the Native American style, or as tumbled or roughly hewn beads in chunky necklaces. Lesser material may be carved into fetishes, such as those crafted by the Zuni. While strong sky blues remain superior in value, mottled green and yellowish material is popular with artisans.

Sources: en.wikipedia.org

Supporting material

Manipulation of CpG-S and CpG-N sequences in the plasmid backbone of DNA vaccines can ensure the success of the immune response to the encoded antigen and drive the immune response toward a TH1 phenotype. This is useful if a pathogen requires a TH response for protection. CpG-S sequences have also been used as external adjuvants for both DNA and recombinant protein vaccination with variable success rates. Other organisms with hypomethylated CpG motifs have demonstrated the stimulation of polyclonal B-cell expansion. The mechanism behind this may be more complicated than simple methylation – hypomethylated murine DNA has not been found to mount an immune response. Most of the evidence for immunostimulatory CpG sequences comes from murine studies. Extrapolation of this data to other species requires caution – individual species may require different flanking sequences, as binding specificities of scavenger receptors vary across species. Additionally, species such as ruminants may be insensitive to immunostimulatory sequences due to their large gastrointestinal load.

It was not discovered to act as a very weak (3.5 orders of magnitude less potent) gabapentinoid until 2015. Baclofen marketed under the brandname of Lioresal was introduced in the United States in 1977 for the treatment of spasticity is chemically similar to phenibut but is usually not considered a gabapentinoid. Mirogabalin, under the brand name Tarlige, was approved for the treatment of neuropathic pain and postherpetic neuralgia in Japan in January 2019. Gabapentenoid consumption appears to be increasing; between 2008 and 2018, gabapentenoid use increased by over 17% averaged worldwide, led by growing consumption in the US, Canada, and northern Europe.

Apiin (apigenin 7-O-apioglucoside), isolated from parsley and celery Apigetrin (apigenin 7-glucoside), found in dandelion coffee Vitexin (apigenin 8-C-glucoside) Isovitexin (apigenin 6-C-glucoside) Rhoifolin (apigenin 7-O-neohesperidoside) Schaftoside (apigenin 6-C-glucoside 8-C-arabinoside)

MASLD incidence is rapidly rising, along with obesity and diabetes, and has become the most common cause of liver disease in developed countries, for adults, teenagers, and children. The percentage of people with MASLD ranges from 9 to 36.9% in different parts of the world. Approximately 20% of the United States and 25% of the Asia-Pacific populations have non-alcoholic fatty liver. Similar prevalence can be found in Europe, although less data is available. MASLD is the most common in the Middle East (32%) and South America (30%), while Africa has the lowest rates (13%). Compared to the 2000s, NAFL and MASH respectively increased 2-fold and 2.5-fold in the 2010s in the USA. MASLD and MASH are more prevalent in Hispanics - which can be attributed to high rates of obesity and type 2 diabetes in Hispanic populations, intermediate in Whites, and lowest in Blacks. MASFLD was observed to be twice as prevalent in men as women. For severely obese individuals, the prevalence of MASLD rises over 90%, and for those with diabetes, over 60%, and up to 20% for normal-weight people. MASLD is present in 65% to 90% of people who have had bariatric surgery, and up to 75% of them have MASH. Ultrasonography and proton NMR spectroscopy studies suggest that about 25% of the population seems to be affected by MASLD or MASH. Although the disease is commonly associated with obesity, a significant proportion of those affected are of normal weight or lean.

Sources: en.wikipedia.org

Frequently asked questions

Is BPC-157 a naturally occurring peptide?

It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.

What does the number 157 in the name indicate?

It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.

Does the molecule contain sulfur or disulfide bonds?

No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.

How is a lyophilised peptide powder stored?

Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.

Network